These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19450754)

  • 1. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
    Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.
    Taimur S; Askar M; Sobecks R; Rybicki L; Warshawsky I; Mossad S
    Transpl Infect Dis; 2014 Feb; 16(1):61-6. PubMed ID: 24251680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
    Parikh CR; Schrier RW; Storer B; Diaconescu R; Sorror ML; Maris MB; Maloney DG; McSweeney P; Storb R; Sandmaier BM
    Am J Kidney Dis; 2005 Mar; 45(3):502-9. PubMed ID: 15754272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
    Junghanss C; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Little MT; Corey L; Storb R
    Blood; 2002 Mar; 99(6):1978-85. PubMed ID: 11877269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
    Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.
    Schaenman JM; Shashidhar S; Rhee C; Wong J; Navato S; Wong RM; Ho DY; Arai S; Johnston L; Brown JM
    Biol Blood Marrow Transplant; 2011 May; 17(5):693-702. PubMed ID: 20736077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
    Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
    Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
    Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.
    Fukuda T; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Martin PJ; Storb RF; Marr KA
    Blood; 2003 Aug; 102(3):827-33. PubMed ID: 12689933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
    Travi G; Pergam SA; Xie H; Boeckh MJ
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):758-60. PubMed ID: 19450762
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.
    Huang YT; Su Y; Kim SJ; Nichols P; Burack D; Maloy M; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):791-799. PubMed ID: 30476551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
    Xuan L; Huang F; Fan Z; Zhou H; Zhang X; Yu G; Zhang Y; Liu C; Sun J; Liu Q
    J Hematol Oncol; 2012 Aug; 5():46. PubMed ID: 22856463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation.
    Slade M; Goldsmith S; Romee R; DiPersio JF; Dubberke ER; Westervelt P; Uy GL; Lawrence SJ
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 28030755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
    Junghanss C; Storb R; Maris MB; Carter RA; Sandmaier BM; Maloney DG; McSweeney PA; Corey L; Boeckh M
    Br J Haematol; 2003 Nov; 123(4):662-70. PubMed ID: 14616970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
    Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
    Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.